Praxis (PRAX) Q2 Loss Widens 90%
Praxis Precision Medicines (NASDAQ:PRAX) is a clinical-stage biopharmaceutical company specializing in therapies for central nervous system (CNS) disorders. On August 4, 2025, it reported financial results for Q2 FY2025. The most notable news from the release was widening operational losses (GAAP), with no recognized revenue and sharply higher research spending. The company posted a GAAP loss per share of ($3.31), missing the consensus estimate of ($3.25) GAAP, with actual GAAP EPS reported as ($3.39), and recognized no revenue, missing GAAP expectations of $0.21 million. These results also represented a sharp deterioration from the year-ago period, as Praxis reported a net loss of $71.1 million (GAAP), compared to a net loss of $32.7 million in Q2 2024 (GAAP). Despite financial setbacks, the quarter was marked by progress in key clinical trials and regulatory wins, suggesting operational momentum but ongoing financial strain.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Praxis Precision Medicines is focused on discovering and developing therapies for neurological conditions such as epilepsy, essential tremor, and rare genetic encephalopathies. Its work is built on two core platforms: Cerebrum and Solidus. The Cerebrum platform targets small molecule drugs, while Solidus develops antisense oligonucleotides, a type of RNA-based therapy.
Source Fool.com
